Chiesi Total Care℠ Patient Support Services Terms and Conditions

These terms and conditions apply to the patient support services offered through the Chiesi Total Care Patient Support Program (the "Program") for Ferriprox® (deferiprone), unless otherwise noted. These patient support service programs may include affordability solutions support, appeals support, benefit verification, patient education support, copay assistance, patient assistance, and Pharmacist support. Patient support services offered through the Program are subject to change.

A patient who receives health care benefits under any plan or program funded in whole or in part by federal or state governments including Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Veterans Affairs (VA), Department of Defense, State Prescription Assistance Plans (SPAPs) (other than health insurance for federal government employees) or any state health care program such as Medicaid, Children's Health Insurance Program, programs funded under Maternal and Child Health Program or programs funded under Social Services Block Grant (collectively, "Government-funded Plans") are not eligible for patient support services that provide financial support through the Program. Only patients with commercial insurance who have a valid prescription for a US Food and Drug Administration-approved indication for Ferriprox are eligible for patient support services that provide financial support through the Program.

Patients residing in or receiving treatment in certain states may not be eligible for certain patient support services of the Program. Patients may not seek reimbursement for value received from the Program. The Program does not obligate the use of any specific medication or healthcare provider. Patients who receive treatment or reside in Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for co-pay assistance for infusion services or routine testing services.

Chiesi Total Care may recommend contacting an independent financial assistance foundation. Independent financial assistance foundations have their own rules for eligibility. Chiesi USA does not fund independent financial assistance foundations, nor does Chiesi Total Care have involvement or influence in independent foundation decision making or eligibility criteria and does not know if a foundation will be able to help you. Chiesi Total Care can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. Chiesi Total Care does not endorse or show preference for any foundation. The foundations recommended to you may not be the only ones that might be able to help you.

Chiesi Patient Education Liaisons ("PELs") may be available to assist you with disease education, provide relative educational or informational resources, and to answer questions you may have about your disease. Chiesi Field Reimbursement Managers ("FRMs") may be available to assist you with your product prescription drug coverage, including prior authorization, appeals, and denials.

PELs and FRMs are employees of Chiesi USA, Inc. PELs and FRMs are not healthcare providers and are not part of your healthcare team. PELs or FRMs will not provide medical care or advice. All treatment decisions should be made by you and your treating healthcare professional. To assist you, PELs and FRMs may need your Information. If you choose to opt out of services by PELs and FRMs, you may do so at any time. Please see Chiesi's Privacy Policy at www.chiesiusa.com/privacy/.

Program benefits may not be sold, purchased, traded, or offered for sale, purchase, or trade. The Chiesi Total Care patient support services are not valid where prohibited by law, taxed, or otherwise restricted. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

This is a voluntary program. Patients who choose not to enroll in the Program will be able to receive medication. Patients may participate in Chiesi Total Care without participating in a patient support services program of Chiesi Total Care. After enrolling in Chiesi Total Care, participants may opt out by contacting the Program, as outlined in the Chiesi Total Care Enrollment and Authorization Form. Patients must renew their eligibility by December 31 of each year to continue to receive support under the Program.

By participating in the Program, participants acknowledge that they understand and agree to comply with the Program Terms and Conditions.

What is Ferriprox® (deferiprone)?

Ferriprox (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:

- thalassemia syndromes
- sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

- in people with myelodysplastic syndrome or Diamond Blackfan anemia
- in children less than 3 years of age

Important Safety Information

What is the most important information I should know about Ferriprox?
Ferriprox can cause serious side effects, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with Ferriprox and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death.

Your healthcare provider will do a blood test before you start Ferriprox and regularly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with Ferriprox if you develop neutropenia or infection.

Stop taking Ferriprox and call your healthcare provider or get medical help right away if you develop any of these symptoms of infection: fever, sore throat or mouth sores, flu-like symptoms, or chills and severe shaking.

It is important for you to have your white blood cell count checked within 24 hours of developing symptoms of an infection to see if you have severe neutropenia (agranulocytosis). Do not delay getting medical care if you are unable to reach your healthcare provider.

Do not take Ferriprox if you are allergic to deferiprone or any of the ingredients in Ferriprox.

Before you take Ferriprox, tell your healthcare provider about all of your medical conditions, including if you: have liver problems, are pregnant or plan to become pregnant. Ferriprox can harm your unborn baby. You should avoid becoming pregnant during treatment with Ferriprox. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Ferriprox. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Ferriprox. You should use effective birth control during treatment with Ferriprox and for at least 6 months after the last dose. For males with female partners who are able to become pregnant, you should use effective birth control during treatment with Ferriprox and for at least 3 months after the last dose. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if Ferriprox passes into your breast milk. Do not breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Avoid drinking alcohol during treatment with Ferriprox tablets (2 times a day). This may cause a faster release of the medicine.

What are other possible side effects of Ferriprox?

Ferriprox can cause serious side effects, including increased liver enzyme levels in your blood. Your healthcare provider should do blood tests to check your liver function before you start and then monthly during treatment with Ferriprox. Your healthcare provider may temporarily stop treatment with Ferriprox if you develop increased liver enzyme levels and they continue to be increased.

Ferriprox can cause decreased levels of zinc in your blood. Your healthcare provider will do blood tests to check your zinc levels before you start and during treatment with Ferriprox and may prescribe a zinc supplement for you if your zinc levels are low.

The most common side effects of Ferriprox in people with thalassemia include nausea, vomiting, stomach-area (abdominal) pain, joint pain, abnormal liver function tests and low white blood cells.

The most common side effects of Ferriprox in people with sickle cell disease or other anemias include fever, stomach-area (abdominal) pain, bone pain, headache, vomiting, pain in arms or legs, sickle cell anemia with crisis, back pain, abnormal liver function tests, joint pain, mouth and throat pain, common cold, low white blood cells, cough and nausea.

Ferriprox may cause a change in urine color to reddish-brown. This is not harmful and is expected during treatment with Ferriprox.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the full Prescribing Information, including boxed WARNING and Medication Guide.

Chiesi
global rare diseases

PP-G-0583 V3.0 2024

Chiesi TOTAL Care℠

Ferriprox® TWICE-A-DAY deferiprone 1000 mg tablets

Ferriprox® deferiprone
1000 mg tablets
500 mg tablets
Oral solution 100 mg/mL